Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment?
Identifieur interne : 001988 ( Main/Corpus ); précédent : 001987; suivant : 001989Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment?
Auteurs : Angela Patrì ; Gabriella FabbrociniSource :
- Journal of the American Academy of Dermatology [ 1097-6787 ] ; 2020.
English descriptors
- KwdEn :
- Betacoronavirus (MeSH), COVID-19 (MeSH), Chemoprevention (MeSH), Coronavirus Infections (drug therapy), Coronavirus Infections (prevention & control), Humans (MeSH), Hydroxychloroquine (therapeutic use), Ivermectin (therapeutic use), Pandemics (prevention & control), Pneumonia, Viral (drug therapy), Pneumonia, Viral (prevention & control), SARS-CoV-2 (MeSH).
- MESH :
- chemical , therapeutic use : Hydroxychloroquine, Ivermectin.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- prevention & control : Coronavirus Infections, Pandemics, Pneumonia, Viral.
- Betacoronavirus, COVID-19, Chemoprevention, Humans, SARS-CoV-2.
DOI: 10.1016/j.jaad.2020.04.017
PubMed: 32283237
PubMed Central: PMC7146719
Links to Exploration step
pubmed:32283237Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment?</title><author><name sortKey="Patri, Angela" sort="Patri, Angela" uniqKey="Patri A" first="Angela" last="Patrì">Angela Patrì</name><affiliation><nlm:affiliation>Section of Dermatology and Venereology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, Italy. Electronic address: patriangela.ap@gmail.com.</nlm:affiliation></affiliation></author><author><name sortKey="Fabbrocini, Gabriella" sort="Fabbrocini, Gabriella" uniqKey="Fabbrocini G" first="Gabriella" last="Fabbrocini">Gabriella Fabbrocini</name><affiliation><nlm:affiliation>Section of Dermatology and Venereology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, Italy.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32283237</idno><idno type="pmid">32283237</idno><idno type="doi">10.1016/j.jaad.2020.04.017</idno><idno type="pmc">PMC7146719</idno><idno type="wicri:Area/Main/Corpus">001988</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001988</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment?</title><author><name sortKey="Patri, Angela" sort="Patri, Angela" uniqKey="Patri A" first="Angela" last="Patrì">Angela Patrì</name><affiliation><nlm:affiliation>Section of Dermatology and Venereology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, Italy. Electronic address: patriangela.ap@gmail.com.</nlm:affiliation></affiliation></author><author><name sortKey="Fabbrocini, Gabriella" sort="Fabbrocini, Gabriella" uniqKey="Fabbrocini G" first="Gabriella" last="Fabbrocini">Gabriella Fabbrocini</name><affiliation><nlm:affiliation>Section of Dermatology and Venereology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, Italy.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Journal of the American Academy of Dermatology</title><idno type="eISSN">1097-6787</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Betacoronavirus (MeSH)</term><term>COVID-19 (MeSH)</term><term>Chemoprevention (MeSH)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (prevention & control)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (therapeutic use)</term><term>Ivermectin (therapeutic use)</term><term>Pandemics (prevention & control)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (prevention & control)</term><term>SARS-CoV-2 (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Hydroxychloroquine</term><term>Ivermectin</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term><term>Pandemics</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term><term>COVID-19</term><term>Chemoprevention</term><term>Humans</term><term>SARS-CoV-2</term></keywords></textClass></profileDesc></teiHeader></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32283237</PMID><DateCompleted><Year>2020</Year><Month>05</Month><Day>21</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-6787</ISSN><JournalIssue CitedMedium="Internet"><Volume>82</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>06</Month></PubDate></JournalIssue><Title>Journal of the American Academy of Dermatology</Title><ISOAbbreviation>J Am Acad Dermatol</ISOAbbreviation></Journal><ArticleTitle>Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment?</ArticleTitle><Pagination><MedlinePgn>e221</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0190-9622(20)30557-0</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jaad.2020.04.017</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Patrì</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Section of Dermatology and Venereology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, Italy. Electronic address: patriangela.ap@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fabbrocini</LastName><ForeName>Gabriella</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Section of Dermatology and Venereology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Acad Dermatol</MedlineTA><NlmUniqueID>7907132</NlmUniqueID><ISSNLinking>0190-9622</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>70288-86-7</RegistryNumber><NameOfSubstance UI="D007559">Ivermectin</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Dermatol Ther. 2020 Jul;33(4):e13565</RefSource><PMID Version="1">32401410</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018890" MajorTopicYN="N">Chemoprevention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007559" MajorTopicYN="N">Ivermectin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>04</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>04</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>5</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32283237</ArticleId><ArticleId IdType="pii">S0190-9622(20)30557-0</ArticleId><ArticleId IdType="doi">10.1016/j.jaad.2020.04.017</ArticleId><ArticleId IdType="pmc">PMC7146719</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Antimicrob Chemother. 2020 Mar 20;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32196083</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2020 Mar 09;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId></ArticleIdList></Reference><Reference><Citation>Actas Dermosifiliogr. 2017 Sep;108(7):643-649</Citation><ArticleIdList><ArticleId IdType="pubmed">28385424</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2020 Apr 3;178:104787</Citation><ArticleIdList><ArticleId IdType="pubmed">32251768</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2018 Nov;159:55-62</Citation><ArticleIdList><ArticleId IdType="pubmed">30266338</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001988 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001988 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32283237
|texte= Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32283237" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |